Focused On-demand Library for rRNA N6-adenosine-methyltransferase ZCCHC4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H5U6

UPID:

ZCHC4_HUMAN

Alternative names:

Zinc finger CCHC domain-containing protein 4

Alternative UPACC:

Q9H5U6; B2RXF6; B4DRD8; B7ZW20; Q5IW78; Q96AN7

Background:

rRNA N6-adenosine-methyltransferase ZCCHC4, also known as Zinc finger CCHC domain-containing protein 4, plays a crucial role in the methylation of adenine in position 4220 of 28S rRNA, a process essential for translation. This specific methylation by ZCCHC4 ensures the proper functioning of the ribosomal RNA, highlighting its significance in protein synthesis.

Therapeutic significance:

Understanding the role of rRNA N6-adenosine-methyltransferase ZCCHC4 could open doors to potential therapeutic strategies. Its pivotal function in the methylation process of rRNA underlines its importance in cellular biology and presents an intriguing target for drug discovery efforts.